Alzamend Neuro Past Earnings Performance
Past criteria checks 0/6
Alzamend Neuro's earnings have been declining at an average annual rate of -24.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-24.4%
Earnings growth rate
-16.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
No updates
Recent updates
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Jul 26
Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
Mar 20We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
Oct 14Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial
Oct 05Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia
Sep 29Alzamend Neuro receives positive pre-IND response from FDA for AL001
Jul 18Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Dec 18Alzamend Neuro closes $14.4M IPO
Jun 17Revenue & Expenses Breakdown
How Alzamend Neuro makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -7 | 3 | 4 |
| 30 Apr 24 | 0 | -10 | 3 | 6 |
| 31 Jan 24 | 0 | -12 | 4 | 8 |
| 31 Oct 23 | 0 | -15 | 6 | 9 |
| 31 Jul 23 | 0 | -15 | 7 | 8 |
| 30 Apr 23 | 0 | -15 | 7 | 7 |
| 31 Jan 23 | 0 | -15 | 8 | 7 |
| 31 Oct 22 | 0 | -13 | 7 | 5 |
| 31 Jul 22 | 0 | -13 | 7 | 6 |
| 30 Apr 22 | 0 | -12 | 7 | 5 |
| 31 Jan 22 | 0 | -10 | 6 | 4 |
| 31 Oct 21 | 0 | -8 | 5 | 3 |
| 31 Jul 21 | 0 | -6 | 4 | 2 |
| 30 Apr 21 | 0 | -5 | 4 | 1 |
| 31 Jan 21 | 0 | -5 | 4 | 1 |
| 31 Oct 20 | 0 | -5 | 4 | 1 |
| 31 Jul 20 | 0 | -5 | 4 | 1 |
| 30 Apr 20 | 0 | -4 | 3 | 1 |
| 31 Jan 20 | 0 | -4 | 3 | 1 |
| 31 Oct 19 | 0 | -4 | 2 | 1 |
| 31 Jul 19 | 0 | -4 | 2 | 3 |
| 30 Apr 19 | 0 | -5 | 1 | 4 |
| 31 Jan 19 | 0 | -4 | 1 | 3 |
| 31 Oct 18 | 0 | -4 | 1 | 3 |
| 31 Jul 18 | 0 | -2 | 1 | 2 |
| 30 Apr 18 | 0 | -1 | 1 | 0 |
| 31 Jan 18 | 0 | -1 | 1 | 0 |
| 31 Oct 17 | 0 | -1 | 1 | 0 |
| 31 Jul 17 | 0 | -1 | 1 | 0 |
| 30 Apr 17 | 0 | -2 | 1 | 0 |
Quality Earnings: ALZN is currently unprofitable.
Growing Profit Margin: ALZN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALZN is unprofitable, and losses have increased over the past 5 years at a rate of 24.4% per year.
Accelerating Growth: Unable to compare ALZN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALZN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: ALZN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.